Company intelligence / Profile preview

Resolution Therapeutics

Edinburgh, Scotland, United Kingdomresolution-tx.com ↗

Ownership: Private
Employees: ~125
Development stage: Phase 1

Overview

Resolution Therapeutics has advanced its lead asset, RTX001, an engineered autologous macrophage cell therapy, into a Phase I/II study ("EMERALD") targeting end-stage liver disease. Preclinical data support its anti-fibrotic and anti-inflammatory potential. The OPAL natural history study is ongoing to provide control data for clinical development. No published human efficacy results yet as of May 2025

Therapeutic areas: Gastroenterology
Modalities: Cell therapy (specifically, engineered autologous macrophages)
Industry: Biotech

Drug pipeline

5 assets

RTX001

4 more assets in the full pipeline.

Partnerships

University of Edinburgh / Centre for Regenerative MedicineScottish National Blood Transfusion ServiceSyncona Investment Management Limited (investor/backer)

Beyond the preview

Go deeper on Resolution Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resolution Therapeutics.